{"id":"sk-pc-b70m","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a personalized neoantigen-based cancer vaccine that uses patient-specific tumor mutations to generate targeted T-cell immune responses. It is intended to work synergistically with checkpoint inhibitors to enhance anti-tumor immunity by training the immune system to recognize and attack cancer cells expressing individual patient mutations.","oneSentence":"SK-PC-B70M is a therapeutic cancer vaccine designed to stimulate immune responses against tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:16.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (in combination with checkpoint inhibitors)"},{"name":"Non-small cell lung cancer (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT01249196","phase":"PHASE3","title":"A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2010-05","conditions":"Alzheimer's Disease","enrollment":256},{"nctId":"NCT00443417","phase":"PHASE2","title":"A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2007-04","conditions":"Alzheimer's Disease","enrollment":188}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SK-PC-B70M","genericName":"SK-PC-B70M","companyName":"SK Chemicals Co., Ltd.","companyId":"sk-chemicals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SK-PC-B70M is a therapeutic cancer vaccine designed to stimulate immune responses against tumor-associated antigens. Used for Melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}